ACM
PHAT icon

ADAR1 Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History

ADAR1 Capital Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,100
Closed -$63.3K – 230
2025
Q1 		$63.3K Hold
10,100
– – 0.01% 175
2024
Q4 		$82K Buy
+10,100
New +$125K 0.02% 185

Other funds holding PHAT

Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Carlyle Group
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

ADAR1 Capital Management's PHAT Position: Q2 2026 in Review

ADAR1 Capital Management held its Phathom Pharmaceuticals (PHAT) position steady in Q2 2026 at 42,900 shares worth $465K. The position accounts for 0.02% of the portfolio, ranked #217.

ADAR1 Capital Management first reported a position in PHAT in Q3 2024 and has held it in 8 quarters since. The position peaked at $712K in Q4 2025. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • ADAR1 Capital Management held 42,900 shares of Phathom Pharmaceuticals worth $465K as of Q2 2026.
  • ADAR1 Capital Management left its Phathom Pharmaceuticals share count unchanged in Q2 2026.
  • Phathom Pharmaceuticals made up 0.02% of ADAR1 Capital Management's portfolio in Q2 2026, its #217 holding.
  • ADAR1 Capital Management first reported a position in Phathom Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • ADAR1 Capital Management's Phathom Pharmaceuticals position peaked at $712K in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.